Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Gains from Investment Securities (2017 - 2025)

Historic Gains from Investment Securities for OptimizeRx (OPRX) over the last 9 years, with Q2 2025 value amounting to $5000.0.

  • OptimizeRx's Gains from Investment Securities fell 9879.52% to $5000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $448000.0, marking a year-over-year decrease of 4189.36%. This contributed to the annual value of $1.8 million for FY2024, which is 1869.95% up from last year.
  • Per OptimizeRx's latest filing, its Gains from Investment Securities stood at $5000.0 for Q2 2025, which was down 9879.52% from $87000.0 recorded in Q1 2025.
  • In the past 5 years, OptimizeRx's Gains from Investment Securities ranged from a high of $8.5 million in Q1 2022 and a low of -$51.1 million during Q4 2021
  • Over the past 5 years, OptimizeRx's median Gains from Investment Securities value was $113500.0 (recorded in 2024), while the average stood at -$2.6 million.
  • Within the past 5 years, the most significant YoY rise in OptimizeRx's Gains from Investment Securities was 206551.58% (2022), while the steepest drop was 22800113.77% (2022).
  • Over the past 5 years, OptimizeRx's Gains from Investment Securities (Quarter) stood at -$51.1 million in 2021, then soared by 102.56% to $1.3 million in 2022, then plummeted by 87.22% to $167000.0 in 2023, then soared by 94.01% to $324000.0 in 2024, then plummeted by 98.46% to $5000.0 in 2025.
  • Its last three reported values are $5000.0 in Q2 2025, $87000.0 for Q1 2025, and $324000.0 during Q4 2024.